|
|
 Previous Article | Table of Contents | Next Article 
B-cell differentiation following autologous, conventional, or T-cell
depleted bone marrow transplantation: a recapitulation of normal B-cell
ontogeny
TN Small, CA Keever, S Weiner-Fedus, G Heller, RJ O'Reilly and N Flomenberg
Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer
Center, New York, NY 10021.
The circulating lymphocytes of 88 consecutive patients following
autologous, conventional, or T-cell depleted bone marrow transplantation
were serially analyzed for B-cell surface antigen expression and function.
In the majority of patients, except for those who developed chronic
graft-versus-host disease, the number of circulating CD20+ B cell
normalized by the fourth posttransplant month. The earliest detectable B
cells normally expressed HLA-DR, CD19, surface immunoglobulin (slg), CD21,
Leu-8, and lacked expression of CD10 (CALLA). In addition, the circulating
B cells expressed CD1c, CD38, CD5, and CD23 for the first year following
transplant, antigens that are normally expressed on a small percentage of
circulating B cells in normal adults, but highly expressed on cord blood B
cells. Similar to cord blood B cells, patient B cells isolated during the
first year following transplant, proliferated normally to Staphylococcus
aureus Cowan strain I (SAC), and produced IgM, but minimal or no IgG when
stimulated with pokeweed mitogen and SAC, unlike normal adult B cells that
produce both. The similar phenotype and function of posttransplant and cord
blood B cells, and their similar rate of decline in patients and normal
children adds further evidence to support the hypothesis that B-cell
differentiation posttransplant is recapitulating normal B-cell ontogeny.
Volume 76,
Issue 8,
pp. 1647-1656,
10/15/1990
Copyright © 1990 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
G. L. Goldberg, O. Alpdogan, S. J. Muriglan, M. V. Hammett, M. K. Milton, J. M. Eng, V. M. Hubbard, A. Kochman, L. M. Willis, A. S. Greenberg, et al.
Enhanced Immune Reconstitution by Sex Steroid Ablation following Allogeneic Hemopoietic Stem Cell Transplantation
J. Immunol.,
June 1, 2007;
178(11):
7473 - 7484.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Lore, R. Seggewiss, F. J. Guenaga, S. Pittaluga, R. E. Donahue, A. Krouse, M. E. Metzger, R. A. Koup, C. Reilly, D. C. Douek, et al.
In Vitro Culture During Retroviral Transduction Improves Thymic Repopulation and Output After Total Body Irradiation and Autologous Peripheral Blood Progenitor Cell Transplantation in Rhesus Macaques
Stem Cells,
June 1, 2006;
24(6):
1539 - 1548.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. He, X. Qiao, P. J. Klasse, A. Chiu, A. Chadburn, D. M. Knowles, J. P. Moore, and A. Cerutti
HIV-1 Envelope Triggers Polyclonal Ig Class Switch Recombination through a CD40-Independent Mechanism Involving BAFF and C-Type Lectin Receptors
J. Immunol.,
April 1, 2006;
176(7):
3931 - 3941.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. M. Horwitz, R. S. Negrin, K. G. Blume, S. Breslin, M. J. Stuart, K. E. Stockerl-Goldstein, L. J. Johnston, R. M. Wong, J. A. Shizuru, and S. J. Horning
Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma
Blood,
February 1, 2004;
103(3):
777 - 783.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. J. Waldschmidt, A. Panoskaltsis-Mortari, R. T. McElmurry, L. T. Tygrett, P. A. Taylor, and B. R. Blazar
Abnormal T cell-dependent B-cell responses in SCID mice receiving allogeneic bone marrow in utero
Blood,
December 15, 2002;
100(13):
4557 - 4564.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Bellucci, E. P. Alyea, E. Weller, A. Chillemi, E. Hochberg, C. J. Wu, C. Canning, R. Schlossman, R. J. Soiffer, K. C. Anderson, et al.
Immunologic effects of prophylactic donor lymphocyte infusion after allogeneic marrow transplantation for multiple myeloma
Blood,
May 29, 2002;
99(12):
4610 - 4617.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. L. Mackall
T-Cell Immunodeficiency Following Cytotoxic Antineoplastic Therapy: A Review
Stem Cells,
January 1, 2000;
18(1):
10 - 18.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
D. Przepiorka, N. A. Kernan, C. Ippoliti, E. B. Papadopoulos, S. Giralt, I. Khouri, J.-G. Lu, J. Gajewski, A. Durett, K. Cleary, et al.
Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease
Blood,
January 1, 2000;
95(1):
83 - 89.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. L. Mackall
T-Cell Immunodeficiency Following Cytotoxic Antineoplastic Therapy: A Review
Oncologist,
October 1, 1999;
4(5):
370 - 378.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
E. M. Novelli, M. Ramírez, W. Leung, and C. I. Civin
Human Hematopoietic Stem/Progenitor Cells Generate CD5+ B Lymphoid Cells in NOD/SCID Mice
Stem Cells,
September 1, 1999;
17(5):
242 - 252.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
B. R. Blazar, P. A. Taylor, R. McElmurry, L. Tian, A. Panoskaltsis-Mortari, S. Lam, C. Lees, T. Waldschmidt, and D. A. Vallera
Engraftment of Severe Combined Immune Deficient Mice Receiving Allogeneic Bone Marrow Via In Utero or Postnatal Transfer
Blood,
November 15, 1998;
92(10):
3949 - 3959.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Gokmen, F. M. Raaphorst, D. H. Boldt, and J. M. Teale
Ig Heavy Chain Third Complementarity Determining Regions (H CDR3s) After Stem Cell Transplantation Do Not Resemble the Developing Human Fetal H CDR3s in Size Distribution and Ig Gene Utilization
Blood,
October 15, 1998;
92(8):
2802 - 2814.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Guillaume, D. B. Rubinstein, and M. Symann
Immune Reconstitution and Immunotherapy After Autologous Hematopoietic Stem Cell Transplantation
Blood,
September 1, 1998;
92(5):
1471 - 1490.
[Full Text]
[PDF]
|
|
|
|
|
|
|
C.S. Zent, C.S. Wilson, G. Tricot, S. Jagannath, D. Siegel, K.R. Desikan, N. Munshi, D. Bracy, B. Barlogie, and A.W. Butch
Oligoclonal Protein Bands and Ig Isotype Switching in Multiple Myeloma Treated With High-Dose Therapy and Hematopoietic Cell Transplantation
Blood,
May 1, 1998;
91(9):
3518 - 3523.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
